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Summary
Purpose:  To  evaluate  the  efﬁcacy,  safety,  and  pharmacokinetics  of  ruﬁnamide  as  an  adjunc-
tive therapy  for  patients  with  Lennox—Gastaut  syndrome  (LGS)  in  a  randomized,  double-blind,
placebo-controlled  trial.
Methods:  We  conducted  a  multicenter  clinical  trial  with  a  4-week  baseline,  a  2-week  titration,
a 10-week  maintenance,  and  either  a  follow-up  visit  or  entry  into  an  open-label  extension.
Patients with  LGS  (4  to  30  years  old)  taking  between  one  and  three  antiepileptic  drugs  weretrial; recruited.  After  the  baseline  period,  patients  were  randomly  assigned  to  ruﬁnamide  or  placebo.Efﬁcacy;
Tolerability;
Pharmacokinetics
The primary  efﬁcacy  variable  was  the  percent  change  in  the  tonic—atonic  seizure  frequency
per 28  days.
Key  ﬁndings:  Of  the  59  patients,  29  were  randomized  to  the  ruﬁnamide  group  and  30  to  the
placebo group.  The  frequency  of  epileptic  seizures  was  signiﬁcantly  decreased  in  the  ruﬁnamide
group than  in  the  placebo  group;  the  median  percent  change  in  frequency  of  tonic—atonic
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seizures  was  −24.2%  and  −3.3%,  respectively,  (p  =  0.003)  and  that  of  total  seizures  was  −32.9%
and −3.1%,  respectively  (p  <  0.001).  Subgroup  analyses  indicated  that  the  efﬁcacy  of  ruﬁnamide
was consistent  independent  of  clinical  background  characteristics.  The  common  treatment-
related adverse  events  in  the  ruﬁnamide  group  were  decreased  appetite  (17.2%),  somnolence
(17.2%), and  vomiting  (13.8%).  Transient  seizure  aggravations  were  observed  in  13  (22.0%)  of  the
59 patients,  though  a  causal  relationship  with  ruﬁnamide  was  suspected  in  only  one  patient.  All
adverse events  were  mild  to  moderate  in  severity.  The  mean  plasma  concentration  of  ruﬁnamide
between  1  and  9  within  12  h  after  administration  was  17.2  g/mL.
Signiﬁcance:  The  present  results  showed  a  favorable  risk-beneﬁt  proﬁle  for  ruﬁnamide  as  an
adjunctive  therapy  for  patients  with  LGS.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under  the  CC  BY-NC-SA
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the  total  seizure  frequency;  50%  responder  rate  for  the
tonic—atonic  seizure  frequency;  percent  change  in  the  fre-
quency  of  seizures  other  than  tonic—atonic  seizures;  andlicense (http://creativecomm
ntroduction
ennox—Gastaut  syndrome  (LGS)  is  one  of  the  most  severe
orms  of  childhood-onset  epileptic  encephalopathy.  This
yndrome  is  characterized  by  various  types  of  epileptic
eizures  (mainly  tonic  seizures),  diffuse  slow  spike-and-
ave  complex  patterns  on  electroencephalogram  (EEG),  and
mpairment  of  cognitive  function  (Arzimanoglou  et  al.,  2009;
eaumanoir,  1985).  The  long-term  mental  and  seizure  prog-
oses  are  generally  devastating  (Arzimanoglou  et  al.,  2009;
eaumanoir,  1985;  Blatter-Ariﬁ,  1991;  Oguni  et  al.,  1996;
htsuka  et  al.,  1990;  Yagi,  1996),  and  appropriate  and  early
ntervention  is  crucial  for  the  treatment  of  patients  with  LGS
o  prevent  mental  deterioration.
However,  therapeutic  evidence  for  antiepileptic  drugs
AEDs)  in  LGS  treatment  is  not  sufﬁciently  established  due
o  its  complex  symptoms  and  low  prevalence  rate  (less  than
.0  per  10,000  population)  (Cowan  et  al.,  1989;  Eriksson  and
oivikko,  1997;  Oka  et  al.,  2006;  Olafsson  and  Hauser,  1999),
hough  several  randomized  controlled  clinical  trials  have
een  conducted  with  some  AEDs:  felbamate  (The  Felbamate
tudy  Group  in  Lennox—Gastaut  Syndrome,  1993),  lamotrig-
ne  (Motte  et  al.,  1997),  topiramate  (Sachdeo  et  al.,  1999),
nd  clobazam  (Ng  et  al.,  2011).  Ruﬁnamide  is  a  recently
eveloped  AED  that  is  being  used  for  the  treatment  of  LGS
n  many  countries  on  the  basis  of  the  results  of  a  random-
zed,  controlled  trial  conducted  in  Europe,  North  America,
nd  Brazil  (Glauser  et  al.,  2008),  but  no  other  randomized,
ontrolled  study  of  ruﬁnamide  for  LGS  has  been  reported.
he  Cochrane  Epilepsy  Group  concluded  that  the  optimum
reatment  for  LGS  remains  uncertain  (Hancock  and  Cross,
013).
Therefore,  we  conducted  a  randomized,  double-blind,
lacebo-controlled  trial  to  evaluate  the  efﬁcacy,  safety,  and
harmacokinetics  of  ruﬁnamide  as  an  adjunctive  therapy  for
atients  with  LGS.
ethods
tudy  design
his  was  a  multicenter,  randomized,  double-blind,  placebo-
ontrolled  trial  in  Japan.The  study  design  of  this  trial  basically  referred  to  the
revious  trial  of  ruﬁnamide  for  LGS  (Glauser  et  al.,  2008).
ligible  patients  were  aged  4—30  years,  weighing  15  kg  or
c
r
w.org/licenses/by-nc-sa/3.0/).
ore.  LGS  was  diagnosed  based  on  a  history  of  tonic  and/or
tonic  seizures  and  atypical  absence  seizures  and  slow  spike-
nd-wave  complex  patterns  on  EEG  within  6  months  before
he  baseline  period.  The  patients  should  have  experienced
t  least  90  seizures  during  the  28  days  before  the  baseline
eriod.  Patients  were  excluded  from  the  study  if  they  expe-
ienced  tonic—clonic  status  epilepticus  during  the  baseline
eriod.  Patients  were  also  excluded  if  they  had  other  clin-
cally  severe  diseases  or  electrocardiographic/laboratory
bnormalities.
This  study  consisted  of  the  following  four  periods:  a  4-
eek  baseline,  a  2-week  titration,  a  10-week  maintenance,
nd  either  a  follow-up  visit  or  entry  into  an  open-label
xtension.  Patients  were  randomized  to  either  ruﬁnamide
r  placebo  in  a  1:1  ratio  according  to  body  weight.  Seizure
requency  data  were  obtained  using  a  diary  recorded  by
aregivers  (mainly  parents,  including  schoolteachers  and
hildcare  workers).  All  caregivers  underwent  standardized
raining  about  seizure  classiﬁcation  and  the  rules  for  diary
ecording  prior  to  the  baseline  period.  In  addition,  a  nation-
ide  meeting  of  the  investigators  was  held  to  standardize
he  methods  applied  to  the  evaluation  of  ruﬁnamide  efﬁcacy
nd  safety.
Seizures  were  classiﬁed  according  to  the  International
eague  Against  Epilepsy  (ILAE)  Classiﬁcation  of  Epileptic
eizures  (Commission  on  Classiﬁcation  and  Terminology  of
he  ILAE,  1981).  Amelioration  of  tonic  seizures  and/or  atonic
eizures  is  essential  for  LGS  patients,  since  these  seizures
ften  result  in  sudden  falls  and  disturb  the  patients’  quality
f  life.  Referring  to  the  previous  study,  the  sum  of  frequen-
ies  of  tonic  seizures  and  atonic  seizures  was  deﬁned  as
he  frequency  of  tonic—atonic  seizures,  and  the  percent
hange  in  the  frequency  per  28  days  was  used  as  the  primary
fﬁcacy  variable  in  this  study.  Percent  change  in  seizure
requency  was  deﬁned  as  [(D  −  B)/B]  ×  100,  where  D  and  B
ere  the  seizure  frequencies  per  28  days  in  the  double-blind
eriod  and  the  baseline  period,  respectively.  The  double-
lind  period  included  the  titration  and  the  maintenance
eriods.
Secondary  efﬁcacy  variables  were:  percent  change  inlinical  global  impression  of  the  patient’s  condition.  The  50%
esponder  rate  was  deﬁned  as  the  percentage  of  patients
ith  at  least  50%  reduction  in  seizure  frequency.  The
ndrome  1629
Figure  1  Patient  disposition.  Safety  and  tolerability  were
assessed  in  all  59  randomized  patients.  *:  One  of  the  29  patients
in the  ruﬁnamide  group  was  excluded  from  the  efﬁcacy  analysis
due to  inappropriate  diagnosis.  Accordingly,  the  efﬁcacy  analy-
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clinical  global  impression  of  the  patient’s  condition,  includ-
ing  seizure  status,  was  evaluated  by  investigators  at  Day
84  using  a  7-point  scale  (markedly  improved,  improved,
slightly  improved,  unchanged,  slightly  worsened,  worsened,
and  markedly  worsened).
We  classiﬁed  the  patients  into  subgroups  based  on  patient
demographics  and  baseline  characteristics:  sex,  age,  time
since  LGS  diagnosis,  underlying  causes,  transition  from
West  syndrome,  seizure  types,  baseline  frequency  of  the
tonic—atonic  seizures,  and  concomitant  AEDs  taken  by  at
least  25%  of  patients  in  ruﬁnamide  and/or  placebo  groups  at
baseline  period.  In  each  subgroup,  we  estimated  the  inter-
group  difference  between  the  ruﬁnamide  and  the  placebo
groups  with  regards  to  tonic—atonic  seizure  frequency.
We  evaluated  the  number  of  patients  who  experi-
enced  adverse  events  (AEs)  and  treatment-related  AEs,  and
their  incidences  after  administration  of  the  blinded  study
drug.  A  causal  relationship  with  the  blinded  study  drug
was  categorized  as  ‘‘not  related’’,  ‘‘possibly  related’’,  or
‘‘probably  related’’  by  investigators.  Treatment-related  AEs
were  deﬁned  as  AEs  for  which  the  causality  was  ‘‘possibly
related’’  or  ‘‘probably  related’’.
Ruﬁnamide  was  supplied  as  100-  and  200-mg  tablets,
with  corresponding  matching  placebo  tablets.  Doses  were
titrated  according  to  a  predetermined  schedule  based  on
body  weight  (Table  1).  The  corresponding  target  dose  was
maintained  during  the  maintenance  period.  One-step  dose
reduction  was  allowed  only  when  investigators  judged  it
necessary  due  to  safety  concerns.  A  rescue  treatment  (e.g.
intravenous  injection  or  rectal  suppository  of  diazepam)  was
permitted  for  transient  seizure  aggravation  including  status
epilepticus.  One  to  three  AEDs  were  allowed  to  be  admin-
istered  concomitantly,  but  they  had  to  remain  unchanged
throughout  the  trial.  Blood  samples  for  pharmacokinetic
analyses  were  collected  at  Day  0  (for  baseline  concentra-
tions  of  concomitant  AEDs),  and  at  Days  28,  56,  and  84  in
the  maintenances  period.  The  plasma  concentrations  of  ruﬁ-
namide  and  concomitant  AEDs  were  measured  using  liquid
chromatography-mass  spectrometry.
This  study  was  conducted  in  accordance  with  the  Dec-
laration  of  Helsinki  and  Good  Clinical  Practice  for  trials  on
medical  products  and  was  approved  by  the  ethical  commit-
tee  of  each  hospital.  Written  informed  consent  was  obtained
from  patients  and/or  their  guardians  prior  to  screening.
Statistical  methods
Sample  size  was  determined  on  the  basis  of  the  results  of
the  previous  trial  of  ruﬁnamide  for  LGS  (Glauser  et  al.,
2008).  We  predeﬁned  the  statistical  signiﬁcance  level  as  0.1
(two-sided)  because  we  thought  that  it  would  be  difﬁcult
to  recruit  a  sufﬁcient  number  of  LGS  patients  for  about
a  year.  Due  to  an  expected  irregular  distribution  of  the
seizure  frequency,  we  calculated  the  statistical  power  by
using  the  simulation-based  approach  known  as  a  resampling
method,  which  directly  re-samples  the  existing  data  without
any  assumption  about  the  underlying  distribution  of  the  sam-
pled  population.  As  the  result  of  this  simulation,  a  sample
size  of  23  patients  in  each  group  was  considered  sufﬁcient
for  a  >80%  power  to  detect  a  signiﬁcant  difference  in  per-
cent  change  in  the  tonic—atonic  seizure  frequency  between
a
p
t
ies were  performed  in  58  patients  (28  in  the  ruﬁnamide  group
nd 30  in  the  placebo  group).
he  ruﬁnamide  group  and  the  placebo  group.  Considering
he  possibility  of  early  discontinuations,  we  set  the  target
umber  of  patients  to  50  in  total.
The  intergroup  comparisons  of  the  seizure  frequency
etween  the  ruﬁnamide  and  the  placebo  groups  were  made
sing  the  Mann—Whitney  U  test.  Subgroup  analyses  based
n  patient  demographics  and  baseline  characteristics  were
ade  by  the  point  estimate  of  the  median  group  differ-
nce  and  its  90%  conﬁdence  interval  (CI)  calculated  by  the
odges-Lehmann  method.  To  evaluate  subgroup  difference,
e  also  made  the  multiple  regression  analysis.  Intergroup
omparison  of  the  50%  responder  rate  in  tonic—atonic
eizure  frequency  was  made  by  Fisher’s  exact  test  and  by
alculating  an  odds  ratio  with  90%  CI.  Intergroup  comparison
f  the  clinical  global  impression  of  the  patients’  condition
as  made  by  the  Mann—Whitney  U  test.
Statistical  analysis  was  performed  using  SAS  for  Windows
version  9.2,  SAS  Institute  Inc.,  Cary,  North  Carolina).  The
igniﬁcance  level  of  all  statistical  analyses  was  <0.1  (two-
ided)  as  noted  above.
esults
atients’  characteristics
ixty-six  Japanese  patients  were  enrolled  during  the  base-
ine  period,  59  of  whom  were  randomized  to  the  treatment
roups  (29  for  ruﬁnamide,  30  for  placebo)  (Fig.  1).  Safety
nd  tolerability  were  assessed  in  these  59  patients.  One
atient  assigned  to  the  ruﬁnamide  group  was  excluded  from
he  efﬁcacy  analysis  due  to  inappropriate  diagnosis.  Patients
n  both  groups  had  similar  demographic  and  baseline
1630  Y.  Ohtsuka  et  al.
Table  1  Dose  titration  schedule.
Trial  day  Daily  dose  by  body  weight  (mg/day)
15.0—30.0  kg  30.1—50.0  kg  50.1—70.0  kg  ≥70.1  kg
Day  1—2  200  400  600  600
Day 3—4  400  800  1200  1200
Day 5—6  800  1200  1800  1800
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the  percentage  of  the  patients  on  three  AEDs  was  higher  inDay 7—8 1000  1800
Day 9 1000  1800
haracteristics.  Most  patients  were  concomitantly  receiving
wo  or  three  AEDs,  though  the  percentage  of  number  and/or
ype  of  concomitant  AEDs  was  partially  different  between
he  ruﬁnamide  and  placebo  groups  (Table  2).  Approxi-
ately  40%  of  patients  had  underlying  causes:  for  example,
uberous  sclerosis  and  cerebral  palsy  in  ﬁve  patients  each;
erebral  dysgenesis,  encephalitis  and  bacterial  meningitis  in
hree  patients  each.
fﬁcacy
he  median  percent  change  in  the  frequency  of  tonic—atonic
eizures  was  −24.2%  in  the  ruﬁnamide  group  and  −3.3%  in
he  placebo  group  (p  =  0.003),  and  that  of  total  seizures
as  −32.9  and  −3.1%,  respectively  (p  <  0.001)  (Fig.  2).
uﬁnamide  adjunctive  therapy  signiﬁcantly  reduced  the
t
A
a
Table  2  Patients’  demographics  and  baseline  characteristics.
Ruﬁna
Male,  n  (%)  17  
Mean age  (SD),  year  16.
4 to  <12,  n  (%)  10  
12 to  <17,  n  (%)  6  
≥17, n  (%)  12  
Mean weight  (SD),  kg  39.
Mean time  since  LGS  diagnosis  (SD),  year  10.
Underlying causes,  n  (%)  12  
Transition from  West  syndrome,  n  (%)  15  
Seizure type,  n  (%)
Multiple  seizure  types  19  
Tonic—atonic  seizure  only  9  
Tonic—atonic  seizure  frequencya
Median  (range)  234.
Total seizure  frequencya
Median  (range)  253.
No. of  concomitant  AEDs,  n  (%)
One  2  
Two 3 
Three 23  
Type of  concomitant  AEDsb,  n  (%)
Valproic  acid  25  
Lamotrigine  13  
Clobazam 12  
LGS: Lennox—Gastaut syndrome, AED: antiepileptic drug.
a Seizure frequency per 28 days.
b Concomitant AEDs taken by at least 25% of patients in ruﬁnamide a2400  2400
2400  3200
requency  of  tonic  seizures  (p  =  0.031),  myoclonic  seizures
p  =  0.021),  and  partial  seizures  (p  =  0.025)  compared  with
lacebo  (Table  3).
The  50%  responder  rate  for  the  tonic—atonic  seizures  was
5.0%  in  the  ruﬁnamide  group  and  6.7%  in  the  placebo  group
p  =  0.074)  (Fig.  3).  The  odds  ratio  was  4.67  (90%CI:  1.15,
8.95).  No  patient  became  free  from  seizures  during  the
tudy.
The  percent  change  in  the  tonic—atonic  seizure  fre-
uency  was  greater  in  the  ruﬁnamide  group  than  in  the
lacebo  group  in  all  subgroups  based  on  patient  demo-
raphics  and  baseline  characteristics  (Table  4).  Althoughhe  ruﬁnamide  group  (Table  2),  the  number  of  concomitant
EDs  did  not  affect  group  difference  between  ruﬁnamide
nd  placebo  groups  (Table  4).
mide  (n  =  28)  Placebo  (n  =  30)
(60.7)  19  (63.3)
0  (7.1)  13.9  (6.1)
(35.7)  13  (43.3)
(21.4)  6  (20.0)
(42.9)  11  (36.7)
0  (19.5)  40.9  (18.0)
5  (7.1)  9.3  (5.8)
(42.9)  13  (43.3)
(53.6)  15  (50.0)
(67.9)  24  (80.0)
(32.1)  6  (20.0)
9  (28.0—22,469.5)  187.8  (8.3—5388.4)
0  (95.4—22,499.4)  296.7  (63.0—5759.7)
(7.1)  1  (3.3)
(10.7)  9  (30.0)
(82.1)  20  (66.7)
(89.3)  28  (93.3)
(46.4)  22  (73.3)
(42.9)  5  (16.7)
nd/or placebo groups at baseline period.
Ruﬁnamide  as  an  adjunctive  therapy  for  Lennox—Gastaut  syndrome  1631
izurFigure  2  Percent  changes  in  the  frequency  of  tonic—atonic  seRegarding  the  subgroup  comparison,  the  multiple
regression  analysis  (response  variable:  frequency  change
in  tonic—atonic  seizures,  explanatory  variables:  sex,
age,  transition  from  West  syndrome,  seizure  type,
b
c
d
T
Table  3  Percent  change  in  the  frequency  of  seizures  other  than  
Seizure  type  Ruﬁnamide  
na Median  (range)  
Tonic  seizures
Baseline  frequency  28  225.1  (21.8—22,469
Double-blind  frequency  28  136.2  (3.1—18,550.
Median %  reduction  28  −24.2  
Atonic seizures
Baseline  frequency  10  21.7  (5.8—2503.4)
Double-blind  frequency  10  17.9  (0.0—733.1)  
Median %  reduction  10  −63.1  
Atypical absence  seizures
Baseline  frequency  12  40.9  (2.8—377.5)  
Double-blind  frequency  12  15.2  (0.0—384.6)  
Median %  reduction  12  −59.0  
Myoclonic seizures
Baseline  frequency  10  26.5  (4.7—3324.7)
Double-blind  frequency  10  10.4  (0.0—863.9)  
Median %  reduction  10  −52.4  
Tonic—clonic seizures
Baseline  frequency  2  6.4  (5.2—7.5)  
Double-blind  frequency  2  3.2  (0.0—6.4)  
Median %  reduction  2  −57.4  
Generalized clonic  seizures
Baseline  frequency 1  11.7  
Double-blind  frequency 1  2.2  
Median %  reduction 1  −81.2  
Partial seizures
Baseline  frequency  4  103.1  (7.0—578.7)  
Double-blind  frequency  4  13.0  (2.2—426.4)  
Median %  reduction  4  −52.2  
a Number of patients who experienced a given type of seizure duringes  (A)  and  total  seizures  (B)  per  28  days  relative  to  baseline.aseline  frequency  of  tonic—atonic  seizures,  and
oncomitant  AEDs)  revealed  that  no  factors  indepen-
ently  affected  the  ruﬁnamide  efﬁcacy  (Supplementary
able).
tonic—atonic  seizures  per  28  days  relative  to  baseline.
Placebo  p  Value
na Median  (range)
.5)  28  124.2  (8.3—5388.4)
5)  28  97.0  (3.4—4828.8)
28  −3.6  0.031
 12  17.7  (1.0—1284.9)
12  29.0  (0.0—1626.7)
12  −6.1  0.221
19  64.3  (1.0—549.6)
19  28.7  (0.3—753.8)
19  −21.1  0.128
 10  171.6  (1.0—1092.0)
10  120.2  (3.7—1470.5)
10  6.6  0.021
10  4.9  (1.0—93.0)
10  5.9  (1.3—81.8)
10  2.4  0.107
0  —
0  —
0  —  —
6  164.9  (24.9—252.0)
6  148.2  (27.7—342.5)
6  4.5  0.025
 the baseline period.
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Figure  3  Percentage  of  patients  with  ≥75%  reduction,  ≥50%  reduction,  ≥25%  reduction,  unchanged,  and  increase  in  the  frequency
of tonic—atonic  seizures.
Table  4  Subgroup  analyses  of  percent  change  in  tonic—atonic  seizure  frequency.
Ruﬁnamide  Placebo  Group  difference  (90%CI)
n  Median  n  Median
All  patients  28  −24.2  30  −3.3  −26.7  (−40.3  to  −11.8)
Sex
Male 17  −37.5  19  5.1  −37.8  (−56.1  to  −20.5)
Female 11  −13.2  11  −10.4  −5.9  (−41.4  to  14.9)
Age (year)
4  to  <12  10  −24.2  13  −10.4  −27.6  (−45.4  to  −7.0)
12 to  <17  6  −25.4  6  −5.1  −23.4  (−127.6  to  26.0)
≥17 12  −22.1  11  1.2  −29.9  (−56.1  to  −5.2)
Time since  LGS  diagnosis  (year)
≤9.9  14  −21.7  16  −2.6  −27.5  (−48.2  to  −5.9)
>9.9 14  −34.5  14  −3.3  −28.1  (−48.6  to  5.2)
Underlying causes
Yes  12  −23.3  13  −7.0  −28.5  (−46.4  to  −4.7)
No 16  −27.1  17  0.5  −27.1  (−47.4  to  −5.8)
Transition from  West  syndrome
Yes  15  −20.8  15  0.5  −20.2  (−40.1  to  −0.3)
No 13  −37.4  15  −8.0  −32.0  (−59.1  to  −5.2)
Seizure type
Multiple  seizure  types 19  −25.8  24  −7.5  −23.7  (−39.9  to  −8.3)
Tonic—atonic  seizure  only  9  −12.5  6  5.5  −28.4  (−75.2  to  1.2)
Baseline seizure  frequency
≤225.1  (tonic—atonic  seizures)  12  −25.5  17  5.1  −30.0  (−60.2  to  −8.3)
>225.1 (tonic—atonic  seizures)  16  −24.2  13  −10.4  −20.9  (−37.9  to  −1.3)
Number and  type  of  concomitant  AEDs
1 or  2  AEDs  5  −17.4  10  −4.6  −14.9  (−39.8  to  7.8)
3 AEDs  23  −37.4  20  −3.3  −29.5  (−48.4  to  −11.4)
Valproic acid  25  −31.6  28  −3.3  −27.9  (−44.0  to  −12.2)
Clobazam 12  −48.4  5  −25.5  −22.9  (−57.9  to  10.9)
Lamotrigine  13  −22.6  22  −9.2  −22.5  (−41.7  to  −2.1)
LGS: Lennox—Gastaut syndrome, CI: conﬁdence interval, AED: antiepileptic drug.
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Table  5  Numbers  of  patients  with  common  treatment-related  adverse  events  by  age.
Ruﬁnamide  Placebo
Age  (year)  4  to  <12  12  to  <17  ≥17  4  to  <12  12  to  <7  ≥17
All  patients  10  6  13  13  6  11
Decreased appetite  1  (10.0)  0  (0.0)  4  (30.8)  0  (0.0)  0  (0.0)  1  (9.1)
Somnolence 0  (0.0)  1  (16.7)  4  (30.8)  1  (7.7)  0  (0.0)  0  (0.0)
Vomiting 1 (10.0) 1  (16.7)  2  (15.4)  0  (0.0)  0  (0.0)  0  (0.0)
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Supplementary  Table  related  to  this  article  can  be
found,  in  the  online  version,  at  http://dx.doi.org/10.1016/
j.eplepsyres.2014.08.019.
The  clinical  global  impression  of  the  patients’  condition
was  signiﬁcantly  different  between  the  ruﬁnamide  group
and  the  placebo  group  (p  =  0.007).  Three  (10.7%)  and  nine
(32.1%)  patients  in  the  ruﬁnamide  group  were  evaluated
as  markedly  improved  and  improved,  respectively,  while  no
patient  was  markedly  improved  or  improved  in  the  placebo
group.
Safety
AEs  occurred  in  93.1%  of  patients  in  the  ruﬁnamide  group  and
70.0%  in  the  placebo  group.  All  AEs  were  mild  to  moderate
in  severity.
Treatment-related  AEs  occurred  in  62.1%  of  patients
in  the  ruﬁnamide  group  and  16.7%  in  the  placebo  group.
The  common  treatment-related  AEs  in  the  ruﬁnamide
group  were  decreased  appetite  (17.2%  for  ruﬁnamide,
3.3%  for  placebo),  somnolence  (17.2%  for  ruﬁnamide,  3.3%
for  placebo),  and  vomiting  (13.8%  for  ruﬁnamide,  0%  for
placebo)  (Table  5).
Transient  seizure  aggravations  were  observed  in  13
(22.0%)  of  the  59  patients  [eight  (27.6%)  in  the  ruﬁnamide
group  and  ﬁve  (16.7%)  in  the  placebo  group].  All  events
required  rescue  medication,  and  all  medications  actually
used  were  diazepam  suppositories.  When  we  deﬁned  status
epilepticus  as  ‘‘the  situation  in  which  a  seizure  persists  for
a  sufﬁcient  length  of  time  or  is  repeated  frequently  enough
that  recovery  between  seizures  does  not  occur’’,  seven
(11.9%)  of  the  59  patients  [ﬁve  (17.2%)  in  the  ruﬁnamide
group  and  two  (6.7%)  in  the  placebo  group]  were  diagnosed
as  having  status  epilepticus  in  the  double-blind  period.
The  remaining  patients  experienced  seizure-clustering.  Four
patients  experienced  transient  seizure  aggravations  several
times  during  this  trial,  but  all  events  were  the  same  type  of
events  in  a  given  patient.
Regarding  the  causal  relationship  with  the  blinded  study
drug,  only  one  of  the  13  patients  was  thought  to  have  a
treatment-related  AE.  This  patient  belonged  to  the  ruﬁ-
namide  group.  He  experienced  status  epilepticus  on  Day  74
while  receiving  2400  mg/day  of  ruﬁnamide.  He  completed
the  study  after  resolution  of  this  event.  Causality  in  the
other  12  patients  was  ruled  out  by  the  investigator  because
these  patients  had  experienced  transient  seizure  aggrava-
tions  before  participating  in  this  trial.
r
t
a
nRash  was  reported  in  three  patients  (two  in  the  ruﬁ-
amide  group  and  one  in  the  placebo  group).  An  11-year-old
oy  in  the  ruﬁnamide  group  experienced  a  rash  on  Day
3,  but  he  continued  the  study  based  on  the  clinical  judg-
ent  of  the  investigator,  because  his  seizures  had  markedly
ecreased  and  his  skin  symptoms  were  not  severe.  His  skin
ymptoms  improved  gradually  1  week  after  onset  as  a  result
f  tentative  cessation  of  ruﬁnamide  and  administration  of
n  anti-allergic  drug.  He  completed  the  study  without  early
iscontinuation.  The  other  patient,  a  9-year-old  boy  in  the
uﬁnamide  group,  developed  a  rash  on  Day  14,  and  he  then
iscontinued  the  study  due  to  the  event.
Fifty-four  (91.5%)  patients  completed  the  trial,  and  ﬁve
8.5%)  discontinued  early  due  to  AEs.  AEs  that  resulted  in  dis-
ontinuation  were  reported  in  four  (13.8%)  patients  in  the
uﬁnamide  group  and  in  one  (3.3%)  in  the  placebo  group.
he  AEs  responsible  for  withdrawal  in  the  ruﬁnamide  group
ere  rash,  purpura,  and  decreased  appetite  (one  patient
ach),  and  vomiting,  dizziness,  and  headache  (one  patient
xperienced  all  three  AEs).  Among  the  patients  who  com-
leted  the  trial,  seven  (25.0%)  in  the  ruﬁnamide  group
nd  one  (3.3%)  in  the  placebo  group  underwent  a one-step
ose  reduction  of  the  blinded  study  drug  due  to  safety
oncerns.
AEs  related  to  laboratory  tests  were  experienced  by  a  few
atients  in  each  treatment  group,  but  no  differences  were
pparent  between  the  two  groups.  No  electrocardiographic
bnormalities  were  observed  in  either  group.
harmacokinetics
lasma  concentrations  [mean  ±  standard  deviation  (SD)]  of
uﬁnamide  between  1  and  9  h  after  administration  were
7.2  ±  6.2  g/mL;  no  effect  was  found  in  relation  to  body
eight  (Fig.  4),  and  no  differences  were  detected  in  rela-
ion  to  age.  The  highest  concentration  was  39.9  g/mL
pproximately  2  h  after  administration,  and  the  correspond-
ng  patient  (an  18-year-old  woman)  discontinued  the  study
ue  to  decreased  appetite,  though  her  seizures  had  very
uch  improved.
Ruﬁnamide  had  no  effect  on  the  plasma  concentrations  of
alproate,  lamotrigine,  or  clobazam.  Due  to  the  small  num-
er  of  patients,  we  were  unable  to  evaluate  the  effects  of
uﬁnamide  on  the  plasma  concentrations  of  other  concomi-
antly  administered  AEDs  or  the  effects  of  concomitantly
dministered  AEDs  on  the  plasma  concentrations  of  ruﬁ-
amide.
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Figure  4  Plasma  concentrations  of  ruﬁnamide  versus
time after  administration  during  the  maintenance  period.
15.0—30.0  kg  (,  n  =  10);  30.1—50.0  kg  (©,  n  =  9);  50.1—70.0  kg
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To  evaluate  the  efﬁcacy,  safety,  and  pharmacokinetics  of×, n  =  5);  ≥70.1  kg  (+,  n  =  2)
iscussion
herapeutic  evidence  for  ruﬁnamide  in  the  treatment  of  LGS
as  been  scarce  because  large-scale  clinical  trials  are  dif-
cult  to  conduct  due  to  the  low  prevalence  rate  of  LGS.
urthermore,  it  is  not  easy  to  accurately  evaluate  the  efﬁ-
acy  of  AEDs  for  LGS  due  to  the  multiple  seizure  types  and
he  high  seizure  frequency  in  this  syndrome.  It  also  might  be
ifﬁcult  for  caregivers  to  identify  all  seizures  throughout  the
ay.  To  obtain  accurate  data  about  seizures,  we  provided  all
aregivers  who  recorded  a  seizure  diary  with  standardized
raining  before  the  start  of  the  baseline  period.  In  partic-
lar,  we  gave  priority  to  consistency  in  seizure  recording
hroughout  the  clinical  study,  because  it  is  essential  for  valid
valuation  of  change  in  seizure  frequency.
Compared  with  the  previous  study  (Glauser  et  al.,  2008),
he  percent  change  in  the  frequency  of  total  seizures  was
ompatible  (−32.9%  vs  −32.7%),  while  the  percent  change
n  the  tonic—atonic  seizure  frequency  was  smaller  (−24.2%
s  −42.5%)  in  the  present  study.  In  the  present  study,  one-
tep  dose  reduction  due  to  safety  concerns  was  permitted;
his  might  have  affected  the  efﬁcacy  evaluation,  consider-
ng  the  dose-dependent  effect  of  ruﬁnamide  in  a  clinically
elevant  concentration  range  (Perucca  et  al.,  2008).  In  addi-
ion,  the  small  sample  size  of  the  study  might  have  affected
fﬁcacy  assessment.  Meanwhile,  the  odds  ratio  of  the  50%
esponder  rate  for  the  tonic—atonic  seizure  frequency  was
reater  in  the  present  study  than  in  the  previous  study  (4.67
s  3.81).  This  fact  provides  further  supportive  evidence  of
uﬁnamide’s  effectiveness.
In  the  present  clinical  trial,  signiﬁcant  intergroup  differ-
nces  were  found  in  tonic  seizures,  myoclonic  seizures,  and
artial  seizures.  However,  this  result  was  somewhat  differ-
nt  from  that  of  the  previous  study  (Glauser  et  al.,  2008),
n  which  absence  seizures  and  atonic  seizures  were  signif-
cantly  improved  by  ruﬁnamide.  Nevertheless,  all  types  of
eizures  were  improved  in  the  ruﬁnamide  group  of  both  stud-
es  as  far  as  the  median  values  were  concerned.  This  fact
uggests  that  ruﬁnamide  can  be  effective  for  various  types
f  seizure  associated  with  LGS,  as  also  indicated  by  other
tudies  (Kim  et  al.,  2012;  Olson  et  al.,  2011).
r
LY.  Ohtsuka  et  al.
LGS  is  an  epilepsy  syndrome  associated  with  various
nderlying  causes  and  a  relatively  wide  age-range  at  onset
f  seizures.  The  clinical  course  of  LGS  is  also  variable,  and  a
ertain  number  of  patients  have  a history  of  West  syndrome
Arzimanoglou  et  al.,  2009;  Beaumanoir,  1985;  Ohtahara
t  al.,  1995;  Ohtsuka  et  al.,  1990).  We  performed  sub-
roup  analyses  of  percent  change  in  tonic—atonic  seizure
requency  to  evaluate  the  effect  of  patient  characteris-
ics  on  the  efﬁcacy  of  ruﬁnamide.  Although  the  number  of
atients  in  each  subgroup  was  too  small  to  make  statistical
omparisons,  the  efﬁcacy  of  ruﬁnamide  seemed  to  be  consis-
ent  independent  of  clinical  background  characteristics.  The
ultivariate  analysis  revealed  that  all  clinical  background
haracteristics  including  sex  and  concomitant  AEDs  were  not
ndependently  related  to  the  efﬁcacy  of  ruﬁnamide.
In  this  study,  ruﬁnamide  was  well  tolerated,  and  AEs  or
reatment-related  AEs  were  mostly  similar  to  those  reported
n  other  studies  (Brodie  et  al.,  2009;  Glauser  et  al.,  2008;
luger  et  al.,  2009,  2010;  Wheless  and  Vazquez,  2010).  All
ransient  seizure  aggravations  including  status  epilepticus
n  this  trial  were  not  severe  and  were  able  to  be  controlled
y  diazepam  suppositories  alone.  The  ratio  of  their  occur-
ence  was  higher  in  the  ruﬁnamide  group  than  in  the  placebo
roup;  however,  of  the  13  patients,  a causal  relationship
as  considered  likely  in  only  one  patient  in  the  ruﬁnamide
roup.  It  is  well  known  that  status  epilepticus,  especially
onconvulsive  status  epilepticus,  is  sometimes  observed
uring  the  clinical  course  of  LGS  (Arzimanoglou  et  al.,  2009;
eaumanoir,  1985;  Hoffmann-Riem  et  al.,  2000).  Almost  all
atients  with  transient  seizure  aggravations  in  the  present
rial  also  had  experienced  similar  events  before  participat-
ng  in  this  trial.  Although  seizure  aggravations  were  also
eported  during  other  clinical  trials  of  ruﬁnamide,  their
ausal  relationships  with  ruﬁnamide  were  not  clearly  proven
Coppola  et  al.,  2010;  Glauser  et  al.,  2008;  Kim  et  al.,
012;  Lee  et  al.,  2013;  Olson  et  al.,  2011).  Considering  all
hese  facts,  it  is  not  likely  that  ruﬁnamide  was  the  main
ause  of  transient  seizure  aggravations  in  the  present  clin-
cal  trial.  Nevertheless,  we  should  carefully  monitor  the
hanges  in  frequency  and  severity  of  seizures  after  admin-
stration  of  ruﬁnamide,  because  aggravation  of  seizures  by
EDs  is  generally  known,  especially  in  patients  with  child-
ood  refractory  epilepsy  such  as  LGS  (Ohtsuka  et  al.,  2006;
erucca  et  al.,  1998;  Sazgar  and  Bourgeois,  2005).
The  limitation  of  the  present  clinical  trial  was  that  the
ample  size  was  relatively  small,  which  could  have  affected
he  evaluations  of  efﬁcacy  and  safety.  However,  the  distri-
ution  of  responders  was  obviously  different  between  the
uﬁnamide  and  placebo  groups,  and  the  analyses  of  multi-
le  efﬁcacy  variables  indicated  that  ruﬁnamide  was  robustly
eneﬁcial  as  an  adjunctive  therapy  for  LGS.  The  other  limi-
ation  was  that  this  was  a  short-term  clinical  trial.  In  order
o  elucidate  the  long-term  efﬁcacy  and  safety  of  ruﬁnamide,
e  are  conducting  an  open-label  extension  study  following
he  present  study.
onclusionuﬁnamide  as  an  adjunctive  therapy  for  patients  with
GS,  we  performed  a  multicenter  randomized,  double-blind
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placebo-controlled  trial  in  Japan.  The  results  of  this  clin-
ical  trial  demonstrated  that  ruﬁnamide  was  an  efﬁcacious
and  well-tolerated  adjunctive  therapy  in  patients  with  LGS
across  a  wide  age  range.
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